[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Ono K, Arimoto H, Wada K, Takahara T, Shirotani T, Shimizu A, Sakai Y, Matsukuma S, Hatanaka K, Inohara T: Multicentric involvement of non-Hodgkin's lymphoma in the central nervous system and testis--case report. Neurol Med Chir (Tokyo); 2004 Sep;44(9):493-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric involvement of non-Hodgkin's lymphoma in the central nervous system and testis--case report.
  • A 73-year-old male presented with diffuse mixed B cell lymphoma with involvement of the central nervous system (CNS) and testis manifesting as mild disorientation and aphasia.
  • Histological examination revealed diffuse mixed B cell type malignant lymphoma in the CNS and testis.
  • Pelvic computed tomography revealed enlargement of the contralateral testis and prostate.
  • Needle biopsy confirmed lymphoma.
  • The patient died 5 months after the initial diagnosis of septic shock.
  • Autopsy examination revealed lymphoma cell invasion of the lung, bone marrow, prostate gland, and thalamus, but without involvement of the systemic lymph nodes.
  • In a patient with an intracranial lymphoma, it is important to determine if the lesion is primary or metastatic and to plan medical treatment including systemic chemotherapy as soon as possible.
  • Improvement of the prognosis of systemic non-Hodgkin's lymphoma with CNS involvement requires the detection and effective treatment of systemic lesions as well as the control of the CNS lesions.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Orchiectomy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15600286.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Kiserud CE, Fosså A, Bjøro T, Holte H, Cvancarova M, Fosså SD: Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer; 2009 Feb 10;100(3):455-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy.
  • Gonadal function was assessed in male lymphoma survivors based on serum hormone levels (LH, FSH, testosterone, SHBG), and was related to treatment, age and observation time.
  • Male patients <or= 50 years at diagnosis treated for Hodgkin's (HL) and/or non-Hodgkin's lymphoma (NHL) at the Norwegian Radium Hospital from 1 January 1980 to 31 December 2002 were included.
  • Five treatment groups were defined: 1: radiotherapy only and/or low gonadotoxic chemotherapy (both HL and NHL)('No/low'), 2: medium gonadotoxicity chemotherapy for NHL ('med-NHL'), 3: medium gonadotoxicity chemotherapy for HL ('med-HL'), 4: highly gonadotoxic chemotherapy for NHL ('high-NHL'), 5: highly gonadotoxic chemotherapy for HL ('high-HL').
  • Compared to those treated with no/low gonadotoxic chemotherapy patients from all other treatment groups had significantly elevated risk for exocrine hypogonadism.
  • Patients from the other treatment groups, except those in the med-NHL group, also had significantly elevated risk for endocrine hypogonadism compared with the group treated with no/low gonadotoxic chemotherapy.
  • Men aged above 50 years at survey were about five times more likely to have endocrine hypogonadism compared with those less than 40 years.
  • Because of the adverse health effects following long-lasting endocrine hypogonadism, gonadal hormones should be assessed regularly in male lymphoma survivors, especially after treatment with alkylating agents and high-dose chemotherapy with autologous stem cell support and in male patients who are 50 years and older.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / physiopathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / physiopathology. Testis / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cross-Sectional Studies. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 1996;35 Suppl 8:73-80 [9073051.001]
  • [Cites] Hum Reprod. 1997 Jan;12(1):73-6 [9043906.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Jan;62(1):64-73 [15638872.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2917-31 [16651642.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1442-9 [17406362.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2825-32 [17515571.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Sep;92(9):3476-82 [17579201.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Nov;92(11):4241-7 [17698901.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 May;52(5):609-16 [10792341.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):679-84 [10942055.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1762-8 [10974623.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Hum Reprod Update. 2001 Jul-Aug;7(4):363-9 [11476348.001]
  • [Cites] Eur J Haematol Suppl. 2001 Jul;64:14-20 [11486395.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1307-11 [11697845.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(9):849-57 [11781645.001]
  • [Cites] Cytotherapy. 2001;3(4):295-305 [12171718.001]
  • [Cites] Eur J Endocrinol. 2003 Aug;149(2):145-52 [12887292.001]
  • [Cites] Eur Urol. 2003 Sep;44(3):322-8 [12932930.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1143-4; author reply 1145 [12966440.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] Cancer. 1982 Feb 1;49(3):418-22 [7059904.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 May;21(5):601-5 [2408897.001]
  • [Cites] Ann Intern Med. 1987 Mar;106(3):354-61 [3544993.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):556-61 [3559649.001]
  • [Cites] Eur J Haematol. 1991 Jan;46(1):33-7 [1988304.001]
  • [Cites] Eur J Cancer. 1991;27(11):1389-92 [1835853.001]
  • [Cites] Br J Haematol. 1994 Sep;88(1):88-93 [7803261.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):145-50 [8777170.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1493-8 [10334536.001]
  • (PMID = 19156143.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2658535
  •  go-up   go-down


3. Kluin-Nelemans HC: Therapy for stage I aggressive non-Hodgkin's lymphoma. Croat Med J; 2002 Oct;43(5):546-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy for stage I aggressive non-Hodgkin's lymphoma.
  • Although radiotherapy was considered sufficient for stage I and limited stage II aggressive non-Hodgkin s lymphoma in the past, new data from randomized studies have shown that intensified chemotherapy or combined modality therapy (multiagent chemotherapy followed by involved field radiotherapy) can result in complete remission in 75-90% of the cases, with 5-year overall survival ranging between 82% and 89%.
  • Patients above 60 years of age, with high lactate dehydrogenase concentration, poor performance, or extranodal disease localized in the testis or central nervous system have a much worse outcome.
  • Therefore, typical extranodal character of this disease (40-57% of the patients show a primary extranodal localization) needs to be recognized and therapy adapted to these subcategories.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402393.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 15
  •  go-up   go-down


Advertisement
4. Kasai T, Moriyama K, Tsuji M, Uema K, Sakurai N, Akazawa S: [Metachronous bilateral primary malignant lymphoma of the testis: a case report]. Nihon Hinyokika Gakkai Zasshi; 2000 May;91(5):526-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronous bilateral primary malignant lymphoma of the testis: a case report].
  • Left high orchiectomy was performed under the diagnosis of primary testicular tumor.
  • Histological findings revealed non-Hodgkin's lymphoma (NHL) of diffuse, mixed type, B cells.
  • About 3 years and a month earlier, he had undergone right high orchiectomy and postoperative radiotherapy (inverted Y irradiation) and chemotherapy (CHOP 5 cycles) for a right testicular tumor whose histological findings were NHL of diffuse, large cell type, B cells.
  • Metachronous bilateral primary malignant lymphoma of the testis is very rare and we discussed each tumor origin by using IgH gene (IgJHDNA) rearrangement as a tumor specific marker of B cell lineage malignant lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neoplasms, Second Primary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Immunoglobulin Heavy Chains / genetics. Male

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10853335.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


5. Vural F, Cagirgan S, Saydam G, Hekimgil M, Soyer NA, Tombuloglu M: Primary testicular lymphoma. J Natl Med Assoc; 2007 Nov;99(11):1277-82
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma.
  • We evaluated clinical features, management and survival of 12 patients with primary testicular non-Hodgkin's lymphoma presented to our hematology unit between January 1992 and July 2006, retrospectively.
  • In the majority of cases, orchidectomy was performed as diagnostic and first-line therapeutic procedures.
  • Dominant histological subtype was diffuse large B-cell non-Hodgkin's lymphoma.
  • All the patients received doxorubicin-based chemotherapy and achieved complete remission.
  • The addition of rituximab and central nervous system prophylaxis with intrathecal combined chemotherapy containing methotrexate, cytarabine and dexametasone were applied to three patients who were recently admitted.
  • Because of the spreading nature and relapse probability at different sites, including central nervous system and contralateral testis, systemic treatment with doxorubicin-based chemotherapy with or without prophylaxis for contralateral testis and the central nervous system seems to improve the outcome of primary testicular lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Disease Progression. Doxorubicin. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Orchiectomy. Prednisone. Prognosis. Retrospective Studies. Survival. Treatment Outcome. Turkey. Vincristine

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2001 Sep;2(2):109-15 [11707851.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):572-76 [543449.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1578-84 [6989476.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2095-102 [7296517.001]
  • [Cites] Clin Radiol. 1981 Nov;32(6):687-92 [7307442.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Oct;8(10):1699-703 [7153080.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2854-8 [10561362.001]
  • [Cites] Blood Rev. 2006 Nov;20(6):319-32 [16884838.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Acta Oncol. 2004;43(8):758-65 [15764222.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):1093-9 [15754007.001]
  • [Cites] Oncology. 2004;67(3-4):211-4 [15557780.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):259-69 [10375083.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):1-7 [9886690.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):59-62 [9020290.001]
  • [Cites] J Urol. 1996 Mar;155(3):943-6 [8583613.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1361-7 [7751880.001]
  • [Cites] Eur J Cancer. 1994;30A(1):1-3 [8142148.001]
  • [Cites] Radiother Oncol. 1993 May;27(2):99-106 [8356234.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):383 [2261381.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):776-81 [3367185.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):297-302 [3339396.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • [Cites] Oncology. 2000 May;58(4):286-92 [10838493.001]
  • [Cites] Br J Urol. 1984 Oct;56(5):525-30 [6398719.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1313-9 [11697846.001]
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):40-6 [11707869.001]
  • (PMID = 18020104.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC2574328
  •  go-up   go-down


6. Suzuki K, Sai S, Kato K, Murase T: [A case of malignant lymphoma of the epididymis]. Hinyokika Kiyo; 2000 Apr;46(4):291-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma of the epididymis].
  • An elastic hard mass was palpable at the upper pole of the left testis.
  • The tumor originated from the epididymis and did not involve the testis or the spermatic cord.
  • Histologically, the tumor was diagnosed as a malignant lymphoma (non-Hodgkin's lymphoma, diffuse mixed cell type, B-cell type).
  • After establishment of the diagnosis of primary epididymal malignant lymphoma, 3 courses of chemotherapy (adriamycin, vincristine, cyclophosphamide, prednisolone) were performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Epididymis. Lymphoma, B-Cell / surgery. Lymphoma, Non-Hodgkin / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Orchiectomy. Prednisolone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10845166.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 9
  •  go-up   go-down


7. Galati G, Sammartino F, Tiziano G, Fiori E, Bononi M, Caputo M, Gazzanelli S: [Non-Hodgkin's lymphoma of the testis. Report of a clinical case and review of the literature]. G Chir; 2002 Jun-Jul;23(6-7):257-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphoma of the testis. Report of a clinical case and review of the literature].
  • [Transliterated title] Il linfoma non Hodgkin del testicolo. Presentazione di un caso clinico e revisione della letteratura.
  • The Authors report a case of primary non-Hodgkin's lymphoma of the testis.
  • Although lymphoma is a rare neoplasm, it is commonest tumor in the elderly age.
  • Surgical therapy is essential but some times it can be associated to radio-chemotherapy.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / surgery. Testicular Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12422782.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 16
  •  go-up   go-down


8. Pectasides D, Economopoulos T, Kouvatseas G, Antoniou A, Zoumbos Z, Aravantinos G, Tsatalas C, Halikia A, Nikolaides C, Kiamouris C, Pappa E, Pavlidis N, Skarlos D, Fountzilas G, Dimopoulos MA: Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience. Oncology; 2000 May;58(4):286-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience.
  • Testicular non-Hodgkin's lymphoma is an uncommon disease and its outcome following chemotherapy and/or radiotherapy has been variable.
  • A retrospective analysis was performed on 26 patients with primary testicular lymphoma treated predominantly with anthracycline-based chemotherapy between 1984 and 1999.
  • There were 11 (42.3%) patients with high grade lymphoma, 12 (46.2%) with intermediate grade, 1 (3.8%) with low grade and 2 (7.7%) were not classified.
  • Chemotherapy was administered to 24 patients including 22 patients who received anthracycline-based chemotherapy.
  • Two stage IEA patients were treated with orchidectomy and adjuvant radiotherapy to the regional lymph nodes without systemic chemotherapy.
  • Chemotherapy alone resulted in a complete remission (CR) in 14 (58.3%) of 24 patients and partial remission in 1 (4.2%), amounting to an overall response rate (RR) of 62.5%.
  • Of the 5 stage I patients who had chemotherapy on an adjuvant basis, 4 (80%) had CR/no evidence of disease.
  • Excluding the 5 stage I patients, chemotherapy resulted in a CR in 10/19 (52.6%) patients and a PR in 1/19 (5.2%), inducing an overall RR of 57.8%.
  • After a median follow-up of 87 months (range 0.13-145.5+ months) the median survival time was 31 months (range 0.13-145.5+ months) and the median time to progression (TTP) 17 months (range 0.13-145.5+ months).
  • Of the 3 patients who relapsed following disease-free status, CNS involvement occurred in 2 stage II patients and contralateral testis involvement in 1 stage IEA, respectively.
  • The other 2 patients who relapsed did not respond to salvage chemotherapy and died.
  • In conclusion, patients with primary testicular lymphoma have a poor outcome, despite the treatment with anthracycline-containing regimens.
  • Treatment with anthracycline-based chemotherapy is recommended in patients at early stages.
  • Because the relapse rate in the CNS and contralateral testis is quite high in most studies, prophylactic CNS treatment and radiotherapy to the other testis should be included in the management of testicular lymphoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10838493.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


9. Lagrange JL, Ramaioli A, Theodore CH, Terrier-Lacombe MJ, Beckendorf V, Biron P, Chevreau CH, Chinet-Charrot P, Dumont J, Delobel-Deroide A, D'Anjou J, Chassagne C, Parache RM, Karsenty JM, Mercier J, Droz JP, Radiation Therapy Group and the Genito-Urinary Group of the French Federation of Cancer Centres: Non-Hodgkin's lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres. Ann Oncol; 2001 Sep;12(9):1313-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres.
  • Primary non-Hodgkin's lymphoma of the testicle is rare.
  • Diffuse large B-cell lymphoma was diagnosed in 75% of cases.
  • Treatment included orchidectomy and radiotherapy and/or chemotherapy.
  • Among patients presenting stage I disease, no difference was found between those treated with combined surgery and chemotherapy or surgery followed or not followed by radiotherapy.
  • This study confirms that non-Hodgkin's lymphoma of the testicle carries a poor prognosis.
  • Systemic adjuvant chemotherapy should be discussed because of the high recurrence rate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697846.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Seymour JF, Solomon B, Wolf MM, Janusczewicz EH, Wirth A, Prince HM: Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma; 2001 Sep;2(2):109-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors.
  • We have analyzed 25 patients with primary testicular large-cell non-Hodgkin's lymphoma managed at our institution from 1972-1998.
  • Twenty-four patients received further therapy after orchiectomy, including chemotherapy in 18 and radiation therapy in 11 (encompassing regional nodes in 8 and the contralateral testis in 6), with 5 patients receiving both modalities.
  • The dominant sites of first failure were extranodal (91%), with prominent involvement of the contralateral testis and cerebral parenchyma.
  • Within the entire cohort, adverse prognostic factors for treatment failure were serum albumin < or = to 3.5 g/dL (P = 0.02), advanced age, advanced stage, and lack of anthracycline-containing chemotherapy (each P < or = to 0.3).
  • Among patients with locoregional disease, albumin < or = to 3.5 g/dL (P = 0.08), no anthracycline-containing chemotherapy (P = 0.15), and fewer than 6 cycles of chemotherapy (P = 0.03) remained predictive.
  • Based on this analysis, we are prospectively evaluating a treatment program for patients with testicular non-Hodgkin's large-cell lymphoma comprising (1) 6 cycles of anthracycline-based chemotherapy, (2) prophylactic radiation therapy to the contralateral testis, and (3) central nervous system prophylaxis with both intrathecal chemotherapy and systemic high-dose methotrexate.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / therapeutic use. Cohort Studies. Humans. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Serum Albumin / metabolism. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707851.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Serum Albumin
  •  go-up   go-down


11. Linassier C, Desablens B, Lefrancq T, Le Prise PY, Harousseau JL, Jacob C, Gandhour C, Haillot O, Lucas V, Leloup R, Escoffre M, Colombat P, Tabuteau S, GOELAMS Study Group: Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma; 2002 Dec;3(3):167-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.
  • Sixteen patients with aggressive primary testicular involvement were analyzed separately from a prospective multicenter series of 494 patients with stage I/II aggressive nonlymphoblastic lymphoma.
  • The treatment strategy included 3 cycles of anthracycline-based chemotherapy followed by regional radiation therapy on inguinal, iliac, and para-aortic lymph nodes and central nervous system (CNS) prophylaxis by intrathecal chemotherapy and brain irradiation.
  • Chemotherapy was stratified by age group.
  • Patients aged 18-60 years received the Groupe Ouest Est d'Etude des Leucemies Aigues et Maladies du Sang (GOELAMS) 02 protocol: 3 monthly cycles of VCAP (vindesine 3 mg/m2 day 1, doxorubicin 80 mg/m2 day 2, cyclophosphamide 1500 mg/m2 day 2, and prednisone 80 mg/m2 days 1-5).
  • The histological subtypes were diffuse large-cell lymphoma in all cases.
  • One patient died from septic shock during the last course of chemotherapy.
  • Relapse in the CNS occurred in only 1 patient and in the contralateral testis in 1 patient.
  • This is the first report of a prospective study in which treatment of testicular non-Hodgkin's lymphoma was precisely defined at diagnosis.
  • Compared to other series, a combination of orchiectomy with 3 cycles of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-derived chemotherapy, regional radiation therapy, and CNS prophylaxis seems to improve prognosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Brain / radiation effects. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Epirubicin / therapeutic use. Humans. Lymph Nodes / pathology. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Prospective Studies. Recurrence. Time Factors. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Lymphoma. 2002 Dec;3(3):173-4 [12521395.001]
  • (PMID = 12521394.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEV protocol; CHOP protocol
  •  go-up   go-down


12. Sénéchal C, Saint F, Petit T, Petit J: [Non-Hodgkin's primitive lymphoma of the testis: long-term prognosis associated with treatment combining systemic and intrathecal chemotherapy]. Prog Urol; 2009 Mar;19(3):209-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's primitive lymphoma of the testis: long-term prognosis associated with treatment combining systemic and intrathecal chemotherapy].
  • [Transliterated title] Lymphomes non hodgkiniens primitifs du testicule : pronostic à long terme associé au traitement combinant chimiothérapie systémique et intrathécale.
  • OBJECTIVES: To evaluate the long-term prognosis of a retrospective series of primitive malignant non-Hodgkin's lymphoma (MNHL) of the testicle treated by orchidectomy and combined systemic and intrathecal chemotherapy.
  • The average age of the patients at the time of diagnosis was 64 years old (46-78).
  • All the patients benefited from an enlarged orchidectomy and received a combination of systemic and intrathecal CHOP and VACP chemotherapy.
  • Five patients (62.5%) responded successfully, one patient had a cerebral relapse stabilized by a second course of chemotherapy.
  • Three patients died, one from septic shock during chemotherapy (IVEA stage), another from mesenteric infarction (IAE stage) and the third from acute coronary thrombosis while in complete remission.
  • CONCLUSION: In spite of a reputedly bleak prognosis, primitive MNHL of the testicle treated with a combination of systemic and intrathecal chemotherapy would seem to be associated with a good specific long-term survival.
  • Unfortunately, the rate of mortality linked to chemotherapy is significant (close to 12.5% in our series) and would not appear to entirely protect against cerebral recurrence.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Testicular Neoplasms / drug therapy. Testicular Neoplasms / mortality
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Humans. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Retrospective Studies. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19268261.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


13. Carlomagno N, Nastro P, Lombari P, Tammaro V, Gargiulo S, Borrelli A, Pettinato G, Renda A: [Polyembrioma of the testis: case report following chemotherapy for non-Hodgkin's lymphoma]. G Chir; 2002 Mar;23(3):65-70
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polyembrioma of the testis: case report following chemotherapy for non-Hodgkin's lymphoma].
  • [Transliterated title] Il poliembrioma del testicolo. Descrizione di un caso insorto dopo trattamento chemioterapico per linfoma non Hodgkin.
  • The reported case is peculiar because the patient was older than the most ones described in the literature and the tumour arose after polychemotherapy for non Hodgkins' disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Second Primary / diagnosis. Testicular Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12109226.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 34
  •  go-up   go-down


14. Vitolo U, Ferreri AJ, Zucca E: Primary testicular lymphoma. Crit Rev Oncol Hematol; 2008 Feb;65(2):183-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma.
  • Primary non-Hodgkin's lymphoma of the testis (PTL) accounts for about 9% of testicular neoplasms and 1-2% of all non-Hodgkin's lymphomas.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common histotype in primary forms; aggressive histologies, especially Burkitt's lymphoma, are prevalent in cases of secondary involvement of testis.
  • Although good results with doxorubicin-containing chemotherapy, followed or not by radiotherapy, have been reported, a high proportion of patients with stage I-II diseases experience aggressive relapses, and patients with advanced disease have a very poor prognosis.
  • PTL has a propensity to disseminate to other extranodal organs, including the controlateral testis, CNS, skin, Waldeyer's ring, lung, pleura, and soft tissue.
  • Orchidectomy followed by R-CHOP combination, with CNS prophylaxis, and prophylactic irradiation of the contralateral testis is the recommended first-line treatment for patients with limited disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Testicular Neoplasms

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962036.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 40
  •  go-up   go-down


15. Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera JE, Cabanillas F, Sarris AH: Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma; 2001 Jun;2(1):40-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?
  • This study was designed to determine response, outcome, and patterns of failure of patients with non-Hodgkin's lymphoma who presented with a testicular mass.
  • Anderson Cancer Center between 1969 and 1999 treated with doxorubicin-based regimens and with radiotherapy and/or intrathecal therapy were considered for this study.
  • All 43 patients had intermediate-grade lymphomas according to the Working Formulation, and all 31 tumors assessed immunophenotypically were large B-cell lymphoma according to the World Health Organization classification.
  • Thirty-four patients achieved complete remission, 19 of whom relapsed, and 5 failed initial therapy.
  • At 10 years, the actuarial probability of failure in the central nervous system was 34% +/- 9% and was 21% +/- 9% in contralateral testis.
  • Doxorubicin-based regimens alone appear unable to cure most patients with lymphoma involving the testis, but CHOP with prophylactic intrathecal therapy and adjuvant scrotal radiotherapy appears promising.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707869.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


16. Strada MR, Frascaroli M, Jedrychowska I, Palumbo R, Poggi G, Bernardo A, Villani G, Melazzini M, Bernardo G: Prospective phase II study of integrated rehabilitative treatment in oncologic patients with neuromotor damage from vertebral metastases. J Clin Oncol; 2004 Jul 15;22(14_suppl):8207

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective phase II study of integrated rehabilitative treatment in oncologic patients with neuromotor damage from vertebral metastases.
  • METHODS: Treatment was performed throughout the following steps, with short-term objectives:.
  • Primary tumor was breast carcinoma in 21 pts (47%), lung cancer in 12 pts (27%), prostate carcinoma in 8 pts (18%), ependyma, testis, non-Hodgkin lymphoma and multiple myeloma in each one of the remaining 4 pts.
  • Most pts (82%) had received combined chemo-radiotherapy; while radiotherapy and chemotherapy alone were given in 6 and 3 pts, respectively.
  • Treatment compliance was good, with no drop-out; improvement of QoL was observed in 93% of pts (43/45) by FACT-G.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016814.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Bar-Shira Maymon B, Yogev L, Marks A, Hauser R, Botchan A, Yavetz H: Sertoli cell inactivation by cytotoxic damage to the human testis after cancer chemotherapy. Fertil Steril; 2004 May;81(5):1391-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli cell inactivation by cytotoxic damage to the human testis after cancer chemotherapy.
  • PATIENT(S): A 31-year-old azoospermic man who underwent cancer cytotoxic chemotherapy for non-Hodgkin's lymphoma at 13 years of age.
  • RESULT(S): A fraction of Sertoli cells (13%) in the atrophic tubules of this patient reexpressed the intermediate filament protein CK-18, which is normally absent after puberty, but not the D2-40 antigen, an Mr 40,000 a-linked membrane glycoprotein, whose loss of expression at puberty marks an irreversible step in Sertoli cell maturation.
  • Tubules with normal spermatogenic progression lined by Sertoli cells negative for CK-18 were also observed.
  • CONCLUSION(S): A fraction of Sertoli cells of this patient initially progressed to full maturation at puberty and reverted to a dedifferentiated state marked by reexpression of CK-18 as a consequence of chemotherapy.
  • This inactivation of Sertoli cells caused by the cytotoxicity of the chemotherapeutic drugs may have contributed to the spermatogenic impairment and resulting infertility.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Infertility, Male / chemically induced. Lymphoma, Non-Hodgkin / drug therapy. Sertoli Cells / drug effects. Testis / drug effects
  • [MeSH-minor] Adult. Cell Differentiation / drug effects. Humans. Immunohistochemistry. Keratins / analysis. Male. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15136109.001).
  • [ISSN] 0015-0282
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


18. Darby S, Hancock BW: Localised non-Hodgkin lymphoma of the testis: the Sheffield Lymphoma Group experience. Int J Oncol; 2005 Apr;26(4):1093-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised non-Hodgkin lymphoma of the testis: the Sheffield Lymphoma Group experience.
  • We evaluated clinical features, management and survival of patients with localised (stage 1E or 2E) testicular non-Hodgkin lymphoma (NHL) presenting to the Sheffield Lymphoma Group between 1972 and 2002.
  • Thirty consecutive eligible patients were identified from the lymphoma database and clinical records of all were reviewed.
  • Twelve (40%) had orchidectomy and chemotherapy, 4 (13%) had orchidectomy and radiotherapy.
  • Three (10%) had orchidectomy, chemotherapy and radio-therapy.
  • Five (17%) had immediate disease progression following orchidectomy or whilst on treatment.
  • A complete response was seen in the remaining 25 (84%) irrespective of treatment modality.
  • Six (20%) died of causes not related to their lymphoma.
  • Twelve (40%) relapsed following a complete response and median time to relapse was 9 months.
  • Only 1 of these relapses was in the central nervous system; 1 in bone, 1 in skin, 2 in the contralateral testis.
  • Primary testicular lymphoma is an uncommon and poor prognosis disease usually affecting older men.
  • The data and experience available to guide the treatment strategies for testicular lymphoma are limited.
  • However, the evidence points to a combined modality approach being the most likely effective treatment, comprising surgery, anthracycline-containing combination chemotherapy with or without prophylactic contralateral testis and regional lymph node irradiation.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery. Neoplasm Recurrence, Local. Orchiectomy. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Combined Modality Therapy. Humans. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies


19. Koukourakis G, Kouloulias V: Lymphoma of the testis as primary location: tumour review. Clin Transl Oncol; 2010 May;12(5):321-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma of the testis as primary location: tumour review.
  • Non-Hodgkin's lymphoma as a primary testicular neoplasm accounts approximately 9% of all testicular malignant tumours and about 1-2% of all non-Hodgkin's lymphoma.
  • This neoplasm is the most common malignant tumour of the testis in the elderly.
  • The most common histotype in primary forms is the diffuse large B-cell lymphoma, whereas more aggressive histologies such as Burkitt's lymphoma are principal founded in cases of secondary involvement of the testis.
  • Despite the fact that responses to doxorubicin- containing chemotherapy, especially in early stages, show good results, relapses are often seen, and the prognosis of this tumour is very poor.
  • Testicular lymphoma often disseminates to other extranodal organs, such as contralateral testis, central nervous system (CNS), lung, pleura, Waldeyer's ring and soft tissue.
  • For patients with limited disease, the recommended first-line treatment is orchiectomy followed by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) combination chemotherapy, with central nervous system (CNS) prophylaxis and prophylactic irradiation of the contralateral testis.
  • In more advanced or relapsed disease, management should follow the worldwide recommendations for nodal diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Lymphoma / diagnosis. Lymphoma / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):40-6 [11707869.001]
  • [Cites] Br J Urol. 1974 Oct;46(5):569-75 [4420636.001]
  • [Cites] Neth J Med. 1991 Aug;39(1-2):92-100 [1961354.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):572-76 [543449.001]
  • [Cites] Am J Med. 1986 Sep;81(3):515-24 [3529957.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):197-204 [11773170.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Neurol Med Chir (Tokyo). 1986 Jan;26(1):68-70 [2425280.001]
  • [Cites] Oncology. 2000 May;58(4):286-92 [10838493.001]
  • [Cites] J Urol. 1969 Aug;102(2):230-2 [4895868.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1578-84 [6989476.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • [Cites] Clin Lymphoma. 2001 Sep;2(2):109-15 [11707851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):652-6 [11849786.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):376-90 [8141430.001]
  • [Cites] Clin Lymphoma. 2002 Dec;3(3):167-72 [12521394.001]
  • [Cites] Australas Radiol. 1991 Aug;35(3):257-60 [1763988.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2854-8 [10561362.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):383 [2261381.001]
  • [Cites] J Urol. 1977 Nov;118(5):783-6 [916101.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):73-7 [7819053.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1361-7 [7751880.001]
  • [Cites] Eur Urol. 2000 Dec;38(6):774-7 [11111200.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):129-33 [14679132.001]
  • [Cites] J Urol. 1994 May;151(5):1162-70 [8158751.001]
  • [Cites] J Urol. 1996 Mar;155(3):943-6 [8583613.001]
  • [Cites] Radiother Oncol. 1993 May;27(2):99-106 [8356234.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1760-4 [7880601.001]
  • [Cites] J Pak Med Assoc. 1994 Apr;44(4):86-8 [8072129.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1182-6 [7850719.001]
  • [Cites] J Urol. 1977 Dec;118(6):1004-7 [336911.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):1093-9 [15754007.001]
  • [Cites] Nouv Rev Fr Hematol. 1995;37(5):267-72 [8700650.001]
  • [Cites] Oncology (Williston Park). 1998 Feb;12(2):185-91; discussion 192-5 [9507520.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Acta Oncol. 2004;43(8):758-65 [15764222.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):259-69 [10375083.001]
  • (PMID = 20466616.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 44
  •  go-up   go-down


20. Rabii R, Mezzour MH, Guessous H, Essaki H, Joual A, Rachid M, Quessar A, Benchekroun S, El Mrini M: [Urogenital lymphoma presenting with obstructive anuria]. Prog Urol; 2004 Feb;14(1):73-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urogenital lymphoma presenting with obstructive anuria].
  • The authors report a case of urogenital lymphoma with multiple sites in a patient presenting with oligo-anuria.
  • Abdominopelvic and scrotal ultrasound demonstrated a prostatic tumour, a hypogastric mass, hepatic nodular lesions and coeliac lymphadenopathy with bilateral ureterohydronephrosis and a heterogeneous intrascrotal mass in contact with the lower pole of the left testis.
  • After a haemodialysis session and ultrasound-guided right percutaneous nephrostomy, pelvic magnetic resonance imaging (MRI) showed a very large pelvic mass between the bladder and the rectum and transrectal biopsy of the mass confirmed the diagnosis of high-grade malignant non-Hodgkin's lymphoma (NHL) with a type B lymphoblastic phenotype.
  • Treatment consisted of chemotherapy according to the LMB 93 protocol.
  • In the light of this case and a review of the literature, the authors discuss the diagnostic, therapeutic and prognostic aspects of this rare site of lymphoma.
  • [MeSH-major] Anuria / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Urogenital Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15098759.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


21. Singh LJ, Devi SB, Singh TA: Primary testicular lymphoma--A case report. J Indian Med Assoc; 2006 Apr;104(4):196-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma--A case report.
  • Primary lymphoma of the testis is more commonly seen in the elderly age group.
  • A 45-year-old Hindu male with histopathological diagnosis of non-Hodgkin's lymphoma of the right testis presented after orchiectomy of the right testis.
  • The patient was put on two cycles of chemotherapy consisting of cyclophosphamide, vincristine, adriamycin and prednisolone at 3- weekly interval followed by external radiation therapy.
  • During follow-up after 7 years he developed left facial nerve palsy and left sided haemiparesis.
  • He was put on cranial radiation therapy with intrathecal methotrexate injections.
  • He responded favourably with the treatment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Middle Aged. Orchiectomy. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910327.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


22. Lasota J, Nordling S, Miettinen M: Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma. Virchows Arch; 2000 Mar;436(3):276-83
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma.
  • They may be primary manifestation of lymphoma or represent a relapse of a previous non-Hodgkin's lymphoma.
  • This report details a testicular large cell lymphoma, which was proven to be large cell transformation of a low-grade follicular lymphoma biopsied 8 years earlier.
  • Initially, a 38-year old man was diagnosed with cervical lymphadenopathy, and biopsy was interpreted as reactive follicular hyperplasia; no treatment was given, and the lymphadenopathy resolved spontaneously.
  • The patient died 7 months later with evidence for intra-abdominal and central nervous system lymphoma after a brief but temporary response to M-BACOD chemotherapy.
  • Orchiectomy specimen and gastroscopic biopsy showed diffuse large B-cell lymphoma (CD20+), which infiltrated between well-preserved tubules in the testis.
  • Histological comparison with 20 testicular lymphomas without previous lymphoma showed tubule infiltration in all cases, suggesting that the tubule-preserving infiltration pattern could be a histological marker for secondary lymphoma involvement in testis.
  • On re-examination, the lymph node 8 years prior was verified as follicular, predominantly small, cleaved cell lymphoma with bcl2-positive follicles.
  • The earlier follicular lymphoma and the subsequent diffuse large cell lymphoma were analyzed using polymerase chain reaction and showed identical sequences of the t(14;18) translocation and immunoglobulin heavy chain gene rearrangement.
  • Analysis of the VH-gene sequences from the follicular lymphoma revealed sequence heterogeneity consistent with ongoing mutation.
  • However, the transformed diffuse large cell lymphoma had no intraclonal variation, with the sequence matching with one of the subclones from the low-grade follicular lymphoma.
  • These results confirm that the large cell transformation of follicular lymphoma occurs in a single follicular lymphoma cell.
  • This case also indicates that the selection of the transformed clone can be part of the natural history of disease and can occur without exposure to chemotherapy.
  • [MeSH-major] Cell Transformation, Neoplastic. Genes, Immunoglobulin. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782887.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


23. Kelleher FC, McDermott R: The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer; 2010 Sep;46(13):2357-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
  • The anaplastic lymphoma kinase gene (ALK) is a gene on chromosome 2p23 that has expression restricted to the brain, testis and small intestine but is not expressed in normal lymphoid tissue.
  • It has similarity to the insulin receptor subfamily of kinases and is emerging as having increased pathologic and potential therapeutic importance in malignant disease.
  • This gene was originally established as being implicated in the pathogenesis of rare diseases including inflammatory myofibroblastic tumour (IMT) and ALK-positive anaplastic large cell lymphoma, which is a subtype of non-Hodgkin's lymphoma.
  • In 2007, an inversion of chromosome 2 involving ALK and a fusion partner gene in a subset of non-small cell lung cancer was discovered.
  • This has been described in ALK-positive anaplastic large cell lymphoma in which ALK is fused to NPM (nucleolar protein gene) and in non-small cell lung cancer where ALK is fused to EML4 (Echinoderm microtubule-associated protein 4).
  • Therapeutic targeting of ALK fusion genes using tyrosine kinase inhibition, vaccination using an ALK specific antigen and treatment using viral vectors for RNAi are emerging potential therapeutic possibilities.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / therapy. Drug Synergism. Gene Amplification. Humans. Lung Neoplasms / genetics. Lung Neoplasms / therapy. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / therapy. Mutation / genetics. Neuroblastoma / genetics. Neuroblastoma / therapy. Pyrimidines / therapeutic use. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases. Receptor, IGF Type 1 / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20451371.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GSK 1838705A; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


24. Autorino R, Lamendola MG, De Sio M, Di Trolio RA, Ferraraccio F, Di Lorenzo G: A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report. Int J Immunopathol Pharmacol; 2007 Apr-Jun;20(2):401-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report.
  • Primary testicular lymphoma is an uncommon testicular tumour.
  • We present a case of a primary non-Hodgkin lymphoma of the testis, describing its clinical and pathological features and discussing our treatment strategy.
  • Light microscopy demonstrated the classic appearance of a diffuse large B-cell lymphoma.
  • No evidence of extra-testicular involvement by lymphoma was found.
  • The histologic analysis confirmed diagnosis of CD-20 positive B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Testicular Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624254.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


25. Müller J: Impact of cancer therapy on the reproductive axis. Horm Res; 2003;59 Suppl 1:12-20
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cancer therapy on the reproductive axis.
  • Cancer therapy includes surgery, chemotherapy and irradiation.
  • Depending on the diagnosis, the location of the neoplasm and the age of the patient, these treatment modalities may be given alone or in combination.
  • All forms of cancer therapy can affect the hypothalamic-pituitary-gonadal axis.
  • The sensitivity of germ cells to cancer therapy also differs between the sexes.
  • With regard to chemotherapy, the possible damage to the gonads is dependent on the total dose and type of agent given.
  • According to current knowledge, the hypothalamic-pituitary axis is not affected by conventional doses of chemotherapy.
  • The present review will focus on the late effects of cancer therapy in children and young adults with acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, brain tumour, Hodgkin's lymphoma or Wilms' tumour, including the adverse effects of bone marrow transplantation.
  • [MeSH-major] Hypothalamo-Hypophyseal System / drug effects. Hypothalamo-Hypophyseal System / radiation effects. Neoplasms / complications. Neoplasms / therapy. Ovary / drug effects. Ovary / radiation effects. Testis / drug effects. Testis / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12566715.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gonadal Steroid Hormones
  • [Number-of-references] 70
  •  go-up   go-down


26. Tomobe M, Miyanaga N, Kawai K, Kikuchi K, Uchida K, Takeshima H, Hasegawa Y, Nagasawa T, Akaza H: [Intrascrotal tumors: a clinicopathologic study of 15 cases]. Nihon Hinyokika Gakkai Zasshi; 2000 Sep;91(9):618-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological diagnoses of 15 patients were 8 malignant lymphomas, 2 paratesticular rhabdomyosarcomas, 2 metastatic tumors (origin; stomach and prostate), 1 epidermoid cyst, 1 cyst of tunica testis, and 1 adenomatoid tumor.
  • As for the cases with malignant lymphoma, all of them were non-Hodgkin's lymphoma whose clinical stages were stage I in 2 cases and stage IV in 6 cases.
  • Five 8 patients died in spite of systemic chemotherapy after an orchiectomy, whereas 2 cases with metastatic tumors died of primary cancer, and two cases with paratesticular rhabdomyosarcoma are still alive and have had no evidence of disease.
  • In particular, some kinds of malignant lymphoma mimic anaplastic seminoma histopathologically.
  • Therefore, accurate diagnosis and precise treatment is important in the patient with intrascrotal tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Diagnosis, Differential. Humans. Infant. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11068425.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


27. Rodriguez J, Romaguera JE, Manning J, Ordonez N, Ha C, Ravandi F, Cabanillas F: Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases. Leuk Lymphoma; 2000 Sep;39(1-2):139-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases.
  • Natural Killer (NK) cell lymphomas, which include the nasal and the "nasal type" varieties, are defined as angiocentric lymphomas in the revised European American Lymphoma (R.E.A.L.) classification.
  • It is associated with the Epstein-Barr virus (EBV) and its response to treatment and prognosis are usually very poor.
  • Thirteen patients with a diagnosis of nasal NK cell lymphoma were treated at UTMDACC from 1987 to 1999.
  • Eleven patients were treated initially with doxorubicin based chemotherapy with or without radiotherapy.
  • Typical immunophenotypes expressing CD2+, CD3- and CD56+ surface markers as well as non rearrangement of T-receptors were present in all patients.
  • Eight patients (62%) responded to therapy; six (46%) with complete response (CR) and two (16%) with partial response (PR).
  • Five patients (38%) were alive, four with no evidence of disease (NED) at 1, 2, 3, and 9 years after treatment, and one patient was alive with disease (AWD) at the time of publication.
  • Six patients had disease progression to extranodal sites including: testis (2), central nervous system (2), lung (1), bone marrow (2), liver (2), peripheral blood (2), and skin (2).
  • In conclusion, the response to doxorubicin-containing regimens is inferior to that of patients with other non-Hodgkin's lymphomas and similar prognostic factors.
  • Because the disease is associated with EBV virus in 90%-100% of the cases and the prognosis is poor, innovative therapies should be tried including immunotherapy that targets the expression of EBV by the tumor with or without myeloablative procedures.
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell / therapy. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Recurrence. Remission Induction. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975392.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


28. Gündüz E, Demirel G, Bal C, Gulbas Z: Evaluation of mobilized peripheral stem cells according to CD34 and aldehyde dehydrogenase expression and effect of SSC(lo) ALDH(br) cells on hematopoietic recovery. Cytotherapy; 2010 Dec;12(8):1006-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary diagnoses were multiple myeloma (n = 14), Hodgkin's lymphoma (n = 7), non-Hodgkin's lymphoma (n = 2), acute myloid leukemia (n = 2), chronic lymphocytic leukemia (n = 1) and germ cell testis tumor (n = 1).
  • [MeSH-major] Graft Survival / immunology. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells / metabolism. Leukemia / therapy. Lymphoma / therapy
  • [MeSH-minor] Adult. Aldehyde Dehydrogenase / metabolism. Antigens, CD34 / metabolism. Blood Component Removal. Cells, Cultured. Cyclophosphamide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoiesis / drug effects. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20735165.001).
  • [ISSN] 1477-2566
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down






Advertisement